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Abstract: 
The conversion of soluble, functional proteins into amyloid fibrils has been linked to the 
development of neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease. In the 
brains of patients with these disorders, the increasing presence of amyloid-containing plaques 
corresponds to neuronal cell death and the worsening of symptoms. However, protein amyloids are 
not merely confined to dying cells. Rather, some show a propensity to be transmitted to, and enter 
adjacent cells and induce the polymerization of the native monomer population. Whether this 
process is directly associated with toxicity or not is still highly debated. In this mini review, we will 
discuss structural polymorphisms of α-synuclein, as determined by super-resolution imaging 
techniques, and how these may be related to neuronal toxicity. 
Introduction: 
Alpha-synuclein is a small, intrinsically-disordered protein. It self-assembles into oligomers and 
subsequently into larger structures such as amyloid fibrils which proliferate in neurons during the 
progression of neurodegenerative disorders such as Parkinson’s disease (PD).  Recent experiments 
have demonstrated the propagation of native, wild-type α-synuclein fibrils in the brains of mice 
demonstrating the capacity of normal proteins to contribute to the spread of PD pathology (1). In 
that work α-synuclein fibrils of both human and mouse origin were injected into mouse brain cells 
resulting in a spreading, PD-like pathology. This “prion-like”1 propagation of α-synuclein aggregates 
has led to a renewed interest in experimental techniques to investigate α-synuclein polymorphisms.  
In the prion field structural polymorphisms of prion proteins determine both their toxicity and 
infectivity (2) however the role of polymorphisms in amyloid related diseases is yet to be 
determined. To date, the role of polymorphism in toxicity for amyloid proteins (a class of proteins 
which include α-synuclein) has only been shown for amyloid β a protein related to Alzheimer’s 
disease (6–8). Furthermore, repeated passage of amyloid through the same species of animal, an 
indication of infectivity, has so far not been observed for amyloid disease in contrast to prion 
diseases (2, 3) and increased expression of normal prion proteins does not cause a corresponding 
rise in disease pathology (2), whereas in PD increased α-synuclein expression does (5). Much work 
remains to be done both on detecting amyloid polymorphisms, characterizing the heterogeneity of 
polymorphisms within cells and elucidating the role of polymorphisms in neurodegeneration.  
                                                          
1 Prions are infectious agents made from protease-resistant misfolded isoforms of host 
protein. 
In prion diseases, where potential role of polymorphisms in neurodegenerative disorders was first 
uncovered, the need for high resolution imaging at the single molecule level to characterize 
heterogeneity has long been recognized. A seminal study was performed by DePace and Weissman 
in which the elongation rates of individual Sup35 fibrils were correlated with the presence of several 
distinct prion strains2 using atomic force microscopy (AFM)(9). Similar studies are lacking in the 
amyloid field where to date the majority of amyloid elongation kinetics experiments have been 
performed in vitro and measure the kinetics at the bulk rather than the single fibril level (10). In this 
mini-review we discuss new optical imaging techniques that have emerged to study the 
polymorphism of amyloids with single molecule resolution. We also summarise their application in 
studies both in vitro and in vivo and how their use has improved the understanding of amyloid 
pathology.  
Amyloid polymorphism, a definition:  
The production of functional proteins post translation is critically dependent on protein folding. 
Folding is sensitive to both, the primary structure of the protein and its cellular environment, and 
the probability of misfolding increases with mutations in the former or disruptions of the latter. 
Misfolded proteins are structurally distinct from their optimally folded counterparts and this 
distinction often implies a change in functionality. For example, functionality may decrease when 
misfolding is accompanied by a change in propensity of the protein to polymerise (or aggregate) 
leading to the range of possible macromolecular structures of the protein (polymorphism) some of 
which may be toxic.  
Previous studies have shown that proteins such as Amyloid β (Aβ) peptides can self-assemble into 
polymorphic fibrillary structures. In particular, in vitro, the morphology of the final fibrils and the 
extent of their heterogeneity (in terms of diameter, length, and degree of twisting) depend upon 
other factors including the absence or presence of agitation, (11, 12) protein concentration, (13, 14) 
physical properties, (pH (15) temperature (16)) and the composition of incubation medium (15, 17).  
A subtler feature of the polymerisation process is the influence that can be exerted by preformed 
seed polymers, which are thought to act as structural templates for subsequent polymerisation and 
hence can influence polymorphism.  It has indeed been shown that different types of seeding 
species leads to polymorphism (11, 12, 18–20). In Jeong et al the authors claim that a mixture of Aβ 
protofibrils and monomers leads to distinct, thicker fibrils that do not display properties found in 
non-templated fibrils such as secondary nucleation. Furthermore, in Pinotsi et al the authors show 
that a large subpopulation of pre-formed fibrils does not seed at all.  
Super-resolution imaging for the study of amyloid polymorphism: 
Optical super-resolution microscopy techniques are a powerful tool to study amyloid-related 
diseases: Using the technique of direct Stochastic Optical Reconstruction Microscopy, dSTORM (21), 
we were able to image in vitro and in cells the morphology of Aβ fibrils with a resolution better than 
20 nm (22). The technique thus affords a spatial resolution approaching that of AFM or SEM 
                                                          
2 In the prion field “strain” refers to misfolded protein isolates that when transferred to 
another host cause prion disease pathology, the presence of several distinct prion strains 
would indicate polymorphism.  
techniques, whilst offering the advantages of specificity and sensitivity that come with all-optical 
techniques. In Figure 1 we show how dSTORM permits the tracking of fibril growth at the single 
molecule level, offering completely new information on the self-assembly process, which is not 
accessible from bulk measurements (19).   
 
Figure 1: α-synuclein elongation assay performed with dSTORM super-resolution microscopy. Small 
fibril seed species, shown in green, are incubated in solution containing monomeric α-synuclein, 
shown in red. α-synuclein seeds were covalently labelled with Alexa Fluor® 568 and monomer with 
Alexa Fluor® 647 dyes, respectively. The images show the time-sequenced growth of individual α-
synuclein fibrils. Clearly, growth takes place from both ends of the seed fibril, extending to several 
micrometers in length after 24 hours. The last image shows a conventional fluorescence microscopy 
image, blurred by optical diffraction. Adapted with permission from (19). Copyright 2014 American 
Chemical Society. 
 
We used small fibrillar seed species of α-synuclein labelled with the Alexa Fluor® 568 dye and 
incubated them in a solution of monomeric α-synuclein that was labelled with Alexa Fluor®647 and 
studied fibril growth using dSTORM. Clearly, growth is seen for individual molecular species. Several 
new insights were obtained from this study that could not have been verified otherwise: First, fibril 
growth clearly proceeds from both ends of the fibril seeds, a hypothesis, that had been the subject 
of considerable scientific debate for lack of conclusive evidence. Secondly, we were able to show 
that the growth rates of individual fibrils varied by orders of magnitude; whilst some fibrils grew 
hardly at all, others extended over disproportional length over the same aggregation period(19). The 
experiment dismissed both random diffusion or the so called ‘stop and go’ models of monomer 
addition, and instead pointed to the likely existence of several ‘misfolding states’, for which 
aggregation can proceed, but which differ in growth rate. It is possible then with such techniques to 
verify whether certain toxic species can ‘force’ healthy species to co-aggregate etc.  The latter is a 
variant of the “prion-like” propagation model of amyloid spreading in disease.   
One of the advantages of super-resolution microscopy is that it is equally amenable to study amyloid 
fibril elongation in cells. Using dSTORM we have recently shown that similarly to our in vitro results 
described above elongation is favoured over nucleation in cells(23). In particular, we externally 
added green-labelled α-synuclein seeds and red-labelled monomeric protein to differentiated SH-
SY5Y cells and observed that seed elongation was dominant over self-nucleation of red-labelled 
monomeric protein. Similarly, this was the case when we added only green-labelled seeds and 
determined seed elongation by endogenous α-synuclein, naturally present in SH-SY5Y and 
embryonic rat ventral mesencephalic neurons, using species specific red- labelled antibodies and 
dSTORM to determine seed elongation. Importantly, toxicity, measured by induction of apoptosis in 
ventral mesencephalic neurons, did not occur upon incubation of neurons with seed fibrils but upon 
addition of monomeric synuclein. In contrast, seed fibrils were protective of neurons incubated with 
monomeric α-synuclein. Moreover, our results showed that exogenously added monomer leads to 
the induction of endogenous α-synuclein aggregation without the two moieties coming into close 
proximity. It thus remains to be determined whether it is cell stress induced by the addition of 
excess monomeric protein or small aggregates (which cannot be resolved by super-resolution 
imaging) that are causative of apoptosis. 
 Figure 2: a) i) and ii) Overlaid DIC and wide-field fluorescence images of ventral-mesencephalic (VM) 
cells treated for 1 h with Alexa Fluor® 568-labeled α-synuclein seed fibrils (green), incubated for 24 h 
in α-synuclein -free medium and immunostained for endogenous α-synuclein with a secondary 
antibody tagged with AF647 (red). b) Zoomed-in dSTORM images of hetero-fibrils formed of 
exogenous seeds (green) elongated by endogenous α-synuclein (red, indicated by an arrow) in 
ventral mesencephalic cells. The top two images correspond to fibrils located in the areas indicated 
by the white arrows in (a). Scale bars correspond to 500 nm. c) Zoomed-in dSTORM images of 
hetero-fibrils formed of exogenous seeds (green) elongated by endogenous α-synuclein (red, 
indicated by an arrow) in SH-SY5Y cells. d) Quantification of the extent of seed elongation by 
endogenous α-synuclein, from data indicated by arrows in (b) and (c) (“Seed  elongation’’) and of the 
size of aggregates consisting of endogenous α-synuclein only, as indicated by an arrowhead in (b) 
(“Nucleation’’). The statistical analysis was performed using an unpaired t-test. ***: p<0.001. The 
experiment was repeated 8 times in SH-SY5Y cells and 7 times in primary ventral mesencephalic cell 
cultures and for each experiment at least 8 randomly chosen areas on the glass coverslip were 
imaged. 
Based on our results one may distinguish two different mechanisms of pathology propagation: the 
transport of pre-formed aggregates, such as exogenously added seeds and an intracellular 
mechanism associated with fibril/aggregate formation which can occur upon increased levels of α-
synuclein in cells. The latter is highly toxic to the cell and while the former appears to be of relativity 
low toxicity the impact of this mechanism on cell survival on the timescale of years remains to be 
seen. Hints can be drawn from studies in patients who had received transplants of ‘healthy’ human 
embryonic ventral mesencephalic tissue to alleviate Parkinson-like symptoms (24, 25). In those 
studies, healthy brain tissue was placed in a host environment with a high proportional of 
pathological α-synuclein aggregates. The timeframe for such healthy embryonic cells to have α-
synuclein inclusion pathology was over 10 years (26) and the patients displayed significant motor 
improvements without requiring pharmacological dopaminergic therapies up to 18 years after 
transplantation (27–29).  This observation of two different mechanisms being involved in PD is 
similar observations in the prion field (2). 
In summary, super-resolution microscopy has opened up the avenue for the study α-synuclein 
polymorphism in vitro, a method that is extendable for similar studies inside a cellular environment. 
The method has further provided insight into fibril kinetics and could, for the first time, correlate the 
type of species with toxicity, highlighting that similar to prion-like diseases, there is a non-toxic 
mechanism of propagation versus one that causes toxicity within. 
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